Based on some previous clinical trial studies in acute and chronic lymphocytic leukemia, there is a marked relationship between CD19-CAR T cell anti-tumor response, and CAR-T cell expansion and persistence [167, 168]. The gene discussed is CD19; the disease is neoplasm.